NCT00699751 2026-02-23
ALSYMPCA
Bayer
Phase 3 Completed
Clinical Trials
16 trialsNCT02955082 2026-02-04
BARCODE2
Institute of Cancer Research, United Kingdom
Phase 2 Active not recruiting
NCT00667199 2023-04-19
BAY88-8223, Does Response Study in HRPC Patients
Bayer
Phase 2 Completed
NCT01741116 2021-02-18
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer
Korean Cancer Study Group
Phase 2 Completed
NCT00477529 2019-11-22
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
Celgene
Phase 1/2 Completed
NCT00286091 2018-10-17
Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer
Amgen
Phase 3 Completed
NCT00928252 2017-08-14
Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer
Queen's Medical Center
Phase 1/2 Completed
NCT00629525 2015-03-03
RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
Duke University
Phase 2 Completed
NCT02208583 2014-08-05
Molecular Phenotype Changes and Personalized Treatment for CRPC
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown
NCT00313482 2012-05-11
PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC
Veeda Oncology
Phase 2 Terminated
NCT00906243 2012-04-04
RNActive®-Derived Therapeutic Vaccine
University of Florida
Phase 1/2 Terminated
NCT00525408 2012-03-12
HRPC
Cadila Pharnmaceuticals
Phase 2 Terminated
NCT01215799 2011-12-15
PROACT
CytRx
Phase 2 Completed
NCT00407251 2010-11-05
Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy
British Columbia Cancer Agency
Phase 2 Completed
NCT00286806 2010-08-24
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
Ascenta Therapeutics
Phase 1/2 Completed
NCT00795171 2010-08-18
Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer
Medical University of Vienna
Phase 2 Unknown